SCHEMBL1848872

SCHEMBL1848872

CS(=O)(=O)CCCC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
SLC22A6 Q4U2R8 2/20 0.50
APEX1 P27695 1/20 0.48
TSHR P16473 5/20 0.48
NFKB1 P19838 1/20 0.48
PMP22 Q01453 1/20 0.48
AKR1B1 P15121 1/20 0.46
GPR84 Q9NQS5 7/20 0.44
PPARG P37231 7/20 0.44
PPARD Q03181 7/20 0.44
PPARA Q07869 7/20 0.44
HDAC11 Q96DB2 5/20 0.44
PTPN1 P18031 3/20 0.44
ALDH1A1 P00352 2/20 0.44
TLR2 O60603 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
FABP4 P15090 2/20 0.44
SLC22A8 Q8TCC7 1/20 0.44
MEN1 O00255 1/20 0.44
ESR1 P03372 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17653549 0.92 LMNA (0.55) LMNASLC22A6APEX1TSHRNFKB1
SCHEMBL2567545 0.90 TSHR (0.57) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL21616868 0.90 TSHR (0.57) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL9340855 0.90 TSHR (0.57) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL4004597 0.90 TSHR (0.57) LMNASLC22A6TSHRNFKB1PMP22
Hydrochloric Acid SCHEMBL9954751 0.88 TSHR (0.55) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL12240 0.83
Hydrochloric Acid SCHEMBL10583532 0.81 APEX1 (0.57) LMNASLC22A6APEX1TSHRNFKB1
SCHEMBL1119147 0.80 PPARG (0.61) LMNAAPEX1TSHRPPARGPPARD
SCHEMBL1119140 0.80 PPARG (0.61) LMNAAPEX1TSHRPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2014-03-20 US claimed
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US claimed
EP-3882252-B1 BETA-LACTAMASE INHIBITORS VENATORX PHARMACEUTICALS INC (US) 2025-11-19 EP disclosed
US-20240294520-A1 AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE PLIANT THERAPEUTICS INC (US) 2024-09-05 US disclosed
CN-113195053-B Amino acid compounds and methods of use 普利安特治疗公司 2024-08-30 CN disclosed
US-20240270742-A1 SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS PLIANT THERAPEUTICS INC (US) 2024-08-15 US disclosed
CN-112689507-B Amino acid compounds having unbranched linkers and methods of use thereof 普利安特治疗公司 2024-07-30 CN disclosed
CN-118256591-A Cyclic peptide compound having high membrane permeability and library comprising same 中外制药株式会社 2024-06-28 CN disclosed
US-11952376-B2 Substituted amino acids as integrin inhibitors PLIANT THERAPEUTICS, INC. (US) 2024-04-09 US disclosed
CN-110869544-B Cyclic peptide compound having high membrane permeability and library comprising same 中外制药株式会社 2024-03-08 CN disclosed
US-20240018376-A1 AQUEOUS ADDITIVE SOLUTION FOR INK COMPOSITION, AQUEOUS COLORANT SOLUTION FOR INK COMPOSITION, INK COMPOSITION, INK COMPOSITION FOR INK JET RECORDING, AND INK JET RECORDING METHOD FUJIFILM CORPORATION (JP) 2024-01-18 US disclosed
EP-0873123-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-10-28 EP disclosed
US-5686454-A PREVENTING LABOR, VASODILATION, DIURESIS, HYPOTENSIVE AGENTS, ANTICOAGULANTS, TREATING DYSMENORRHEA MERCK & CO., INC. (US) 1997-11-11 US disclosed
US-5648352-A STOPPING LABOR MERCK & CO., INC. (US) 1997-07-15 US disclosed
WO-1997017070-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1997-05-15 WO disclosed
EP-0708765-A4 SUBSTITUTED PIPERAZINYLCAMPHOR DERIVATIVES AS OXYTOCIN ANTAGONISTS MERCK & CO INC (US) 1996-06-26 EP disclosed
EP-0708765-A1 SUBSTITUTED PIPERAZINYLCAMPHOR DERIVATIVES AS OXYTOCIN ANTAGONISTS MERCK & CO. INC. (US) 1996-05-01 EP disclosed
WO-1995002587-A1 SUBSTITUTED PIPERAZINYLCAMPHOR DERIVATIVES AS OXYTOCIN ANTAGONISTS MERCK & CO., INC. (US) 1995-01-26 WO disclosed
WO-1993006092-A1 PIPERAZINYL (SULFONYL)AMIDE DERIVATIVES OF CAMPHOR AS OXYTOCIN ANTAGONISTS MERCK & CO., INC. (US) 1993-04-01 WO disclosed
EP-0532097-A1 Piperazinyl(sulfon)amide derivatives of camphor as oxytocin antagonists MERCK & CO. INC. (US) 1993-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11952376-B2 Substituted amino acids as integrin inhibitors ITGB6, ITGA1, ITGB1 LMNA 2121/4885SLC22A6 331/4885APEX1 4384/4885
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS GRK5, GPBAR1, GPR55 LMNA 3285/4885SLC22A6 1327/4885APEX1 4136/4885
US-20240294520-A1 AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE ITGA2B, ITGB6, ITGB1 LMNA 1777/4885SLC22A6 778/4885APEX1 2874/4885
US-20240270742-A1 SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS ITGB6, ITGA1, ITGB1 LMNA 2121/4885SLC22A6 331/4885APEX1 4384/4885
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 LMNA 133/4885SLC22A6 2887/4885APEX1 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.